Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 02 Nov, 14:00 UTC

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.

businessscience

Sources

• T2Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilienceBioPharma Dive / Healthcare Dive / MedTech Dive02 Nov, 14:00